Yabao Pharmaceutical Group Co., Ltd

600351

CNE000001CM5

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 28/06/2024 am IST			5-day change	1st Jan Change
5.61 ^CNY	+0.72%		-1.75%	-18.70%

25/04	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
25/04	Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.

April 24, 2024

From April 1, 2024 to April 23, 2024, the company has repurchased 0 shares, representing 0% for CNY 0 million. With this, the company has completed the repurchase of 49,999,929 shares, representing 6.59% for CNY 322.09 million under the buyback announced on May 9, 2023.

Latest news about Yabao Pharmaceutical Group Co., Ltd

Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	24/04	CI
Yabao Pharmaceutical Group Co., Ltd's Equity Buyback announced on May 9, 2023 has closed with 49,999,929 shares, representing 6.59% for CNY 322.09 million.	23/04	CI
Yabao Pharma Gets Nod to Register Asthma Drug Montelukast Sodium Granules	16/04	MT
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	02/04	CI
Yabao Pharmaceutical Group Co., Ltd announces an Increase in Equity Buyback.	05/02	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	27/23/27	CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	10/23/10	CI
Yabao Pharmaceutical Group Co., Ltd(XSSC:600351) added to S&P Global BMI Index	18/23/18	CI
Hunan Caprico Biotechnologies Co., Ltd. announced that it has received funding from Guangzhou Huangpu Biomedical Fund Management Co., Ltd., Yabao Pharmaceutical Group Co., Ltd	18/23/18	CI
Yabao Pharmaceutical Takes Over Rights of Traditional Chinese Medicine for 26 Million Yuan	08/23/08	MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	03/23/03	CI
Tranche Update on Yabao Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on May 9, 2023.	04/23/04	CI
Yabao Pharmaceutical Group Co., Ltd commences an Equity Buyback Plan for CNY 300 million worth of its shares, under the authorization approved on April 24, 2023.	09/23/09	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	25/23/25	CI
Yabao Pharmaceutical Unit Submits FDA Application for Osteoarthritis Drug	13/23/13	MT
Yabao Pharmaceutical Unit's Sorafenib Tablets Enters US Markets	16/22/16	MT
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22/22/22	CI
Fineimmu announced that it has received CNY 100 million in funding from Yabao Pharmaceutical Group Co., Ltd, Panacea Venture Management Co., Ltd. and another investor	03/22/03	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	27/22/27	CI
Yabao Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	27/22/27	CI
Indian Indices End Lower; Bajaj Finance Slides 7%	27/22/27	MT
Lupin to Market Pediatric Medicines in China Under New Deal with Yabao Pharmaceutical	27/22/27	MT

Chart Yabao Pharmaceutical Group Co., Ltd

Duration

Period

Chart Yabao Pharmaceutical Group Co., Ltd

More charts

Company Profile

YABAO PHARMACEUTICAL GROUP CO. LTD is a China-based company, principally engaged in the research and development, production and distribution of pharmaceuticals. The Company mainly provides light pastes, tablets, injections, capsules, oral liquids, bulk drugs and other pharmaceutical products. The Company is also engaged in the wholesaling and trading of pharmaceuticals. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

28/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
YABAO PHARMACEUTICAL GROUP CO., LTD	-18.70%	556M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.76%	43.77B
OTSUKA HOLDINGS CO., LTD.	+28.00%	22.83B
SANDOZ GROUP AG	+20.25%	15.56B
CIPLA LIMITED	+18.82%	14.34B
ZYDUS LIFESCIENCES LIMITED	+55.83%	12.96B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-12.70%	6.41B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.65%	5.69B